For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Melanocortin

PT-141

Also known as: Bremelanotide

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It is FDA-approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women only.

Real-time market data

Pricing for PT-141

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$4.53/mg

range $0.50–$10.00/mg

Sellers

82

from $0.00

45-day trend

-22.7%

vs 45-day avg $/mg

69 of 82 sellers have a current price· 40 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for PT-141

130 third-party tests across 28 vendors. Each card links to the full report.

All 130 COAs for PT-141 →
Measured purity 98.9%–100.0% across 80 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.79 %
Jun 2026
Janoshik Analytical Limited

For

PT-141

by Verified Peptides

Aggregated · 3rd-party listing
99.94 %
Jun 2026
ILS Labs Strong

For

PT-141

by Orbitrex Peptides· batch PT10726US

✓ Vendor-published
99.74 %
Jun 2026
Kovera Labs

For

PT-141

by Peptide Partners· batch PT202605

COA on file
Aggregated · 3rd-party listing
99.91 %
May 2026
Janoshik Analytical Limited

For

PT-141

by EZ Peptides· batch EZP-PT1005172026-08

✓ Vendor-published
99.92 %
May 2026
Janoshik Analytical Limited

For

PT-141

by EZ Peptides· batch EZP-PT1005172026-08

COA on file
✓ Vendor-published
99.88 %
May 2026
ILS Laboratories

For

PT-141

by Ion Peptide· batch PT10-05202026

COA on file
Aggregated · 3rd-party listing
99.89 %
May 2026
ILS Labs Strong

For

PT-141

by Sunrise Bioresearch· batch PT10MAY26-01

✓ Vendor-published
99.89 %
May 2026
ILS Laboratories

For

PT-141

by Sunrise Bioresearch· batch PT10MAY26-01

COA on file
✓ Vendor-published
99.86 %
May 2026
Kovera Labs

For

PT-141

by Reta One Labs· batch PT100526

COA on file
Aggregated · 3rd-party listing
99.93 %
May 2026
ILS Labs Strong · HPLC

For

PT-141

by Crush Research· batch CRPT-10-2605-1

Aggregated · 3rd-party listing
99.78 %
May 2026
Janoshik Analytical Limited · HPLC

For

PT-141

by Verified Peptides· batch PT03261310J

Aggregated · 3rd-party listing
99.25 %
May 2026
Horizon Analytical

For

PT-141

by Pepsgpt· batch P-2061592-P

Aggregated · 3rd-party listing
99.87 %
May 2026
Freedom Diagnostics Moderate

For

PT-141

by Real Peptides· batch White Cap

Aggregated · 3rd-party listing
99.77 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

PT-141

by Verified Peptides· batch cmpds11k4002104l7jqg8dx52

Aggregated · 3rd-party listing
99.93 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

PT-141

by Skye Peptides· batch PT26-10-002

Aggregated · 3rd-party listing
99.76 %
Apr 2026
MDx BioAnalytical Laboratory Strong · HPLC

For

PT-141

by BioLongevity Labs· batch 25-3-43136

Aggregated · 3rd-party listing
99.92 %
Apr 2026
Freedom Diagnostics Moderate

For

PT-141

by IDUN Peptides· batch PT10-260331

✓ Vendor-published
99.80 %
Apr 2026
Kovera Labs

For

PT-141

by Ion Peptide· batch PT10-04202026

COA on file
Aggregated · 3rd-party listing
99.95 %
Apr 2026
ILS Labs Strong

For

PT-141

by NG Peptide· batch PT10-1639

Aggregated · 3rd-party listing
99.90 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

PT-141

by Peptidegurus· batch 24th Feb 2026

Aggregated · 3rd-party listing
99.01 %
Apr 2026
Vanguard Laboratory Strong

For

PT-141

by Arcane Peptides· batch PT402

✓ Vendor-published
99.91 %
Apr 2026
Kovera Labs

For

PT-141

by Ion Peptide· batch PT10-04072026

COA on file
Aggregated · 3rd-party listing
99.86 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

PT-141

by Peptide Plugs· batch 112-U

Aggregated · 3rd-party listing
99.92 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

PT-141

by Qihang Peptide· batch 4

Research depth

16 citations indexed for PT-141

All research on PT-141 →

review · 2026

Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov

Background Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition affecting adult women and is associated with significant impairments in quality of life and interpersonal relationships.

review · 2026

Phytochemical-based nanomedicine as a promising therapeutic strategy for erectile dysfunction

Erectile dysfunction (ED) is a common condition among aging men, often associated with metabolic disorders, diabetes mellitus, hypertension, oligozoospermia, cardiovascular disease, sedentary lifestyles, chronic infections, and inflammation.

review · 2026

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives

Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.

review · 2026

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

Background Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.

review · 2025

Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions

Introduction Erectile dysfunction (ED) pathophysiology involves complex interactions between vasculogenic, hormonal, and neurological mechanisms, with endothelial dysfunction and oxidative stress playing crucial roles.

rct · 2015

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.